These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 912593

  • 1. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ, Bone JM, Anderson TJ, Robson JS.
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract] [Full Text] [Related]

  • 2. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM, Ellis HA, Ward MK, Simpson W, Kerr DN.
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A, Bordier P, Gueris J, Sebert JL, Marie P, Ferrière C, Bedrossian J, DeLuca HF.
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract] [Full Text] [Related]

  • 4. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
    Postlethwaite RJ, Houston IB.
    Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
    [No Abstract] [Full Text] [Related]

  • 5. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG, Ledingham JG, Norman AW, Oliver DO, Preston C, Russell RG, Small DG, Smith R, Warner GT, Woods CG.
    Proc Eur Dial Transplant Assoc; 1973 May; 10(0):202-9. PubMed ID: 4802654
    [No Abstract] [Full Text] [Related]

  • 6. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ, Catto GR, Macleod M.
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract] [Full Text] [Related]

  • 7. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L, Mines M, Mazur Y, Sklan D, Garmizo AL, Jancu J, Israeli M, Malul M.
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [Abstract] [Full Text] [Related]

  • 8. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P, Zingraff J, Gueris J, Jungers P, Marie P, Pechet M, Rasmussen H.
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N, Catto GR, Edward N, Fraser RA, O'Riordan JL, Papapoulos SE, Adami S.
    Proc Eur Dial Transplant Assoc; 1980 Jan; 17():543-7. PubMed ID: 6972529
    [Abstract] [Full Text] [Related]

  • 10. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [Abstract] [Full Text] [Related]

  • 11. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE, Bordier PJ, Gueris J, Chanard J, Marie P, Ferriere C, Osario M, Bedrossian J, de Luca HF.
    Proc Eur Dial Transplant Assoc; 1976 Jul; 12():227-36. PubMed ID: 935115
    [Abstract] [Full Text] [Related]

  • 12. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE, Bordier PJ, Gueris J, Chanard J, Marie P, Ferriere C, Osario M, Bedrossian J, De Luca HF.
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract] [Full Text] [Related]

  • 13. Symptomatic renal osteodystrophy after renal transplantation: treatment with 1-alpha-hydroxycholecalciferol.
    Williams PS, Hillis AN, Carty AJ, Sells RA, Bone JM.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2227-8. PubMed ID: 3274500
    [No Abstract] [Full Text] [Related]

  • 14. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
    Kanis JA, Henderson RG, Heynen G, Ledingham JG, Russell RG, Smith R, Walton RJ.
    Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833
    [Abstract] [Full Text] [Related]

  • 15. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
    Popovtzer MM, Levi J, Bar-Khayim Y, Shasha SM, Boner G, Bernheim J, Chaimovitz C, Rubinger D, Gafter U, Gazit D.
    Bone; 1992 Jun; 13(5):369-77. PubMed ID: 1419378
    [Abstract] [Full Text] [Related]

  • 16. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG, Goldstein DA, Malluche HH.
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract] [Full Text] [Related]

  • 17. Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Nielsen SP, Binderup E, Godtfredsen WO, Jensen H, Ladefoged J.
    Proc Eur Dial Transplant Assoc; 1976 Oct; 12():221-6. PubMed ID: 935114
    [Abstract] [Full Text] [Related]

  • 18. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
    Chesney RW, Hamstra A, Jax DK, Mazess RB, DeLuca HF.
    Contrib Nephrol; 1980 Oct; 18():55-71. PubMed ID: 7353380
    [No Abstract] [Full Text] [Related]

  • 19. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ, Catto GR.
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [Abstract] [Full Text] [Related]

  • 20. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM, Goodwin FJ, Hately W, Marsh FP, O'Riordan JL, Papapoulos SE.
    Br Med J; 1977 Sep 17; 2(6089):721-3. PubMed ID: 912269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.